Cargando…

Efficacy and Safety of Plasma Exchange with 5% Albumin to Modify Cerebrospinal Fluid and Plasma Amyloid-β Concentrations and Cognition Outcomes in Alzheimer’s Disease Patients: A Multicenter, Randomized, Controlled Clinical Trial

Background: Studies conducted in animal models and humans suggest the presence of a dynamic equilibrium of amyloid-β (Aβ) peptide between cerebrospinal fluid (CSF) and plasma compartments. Objective: To determine whether plasma exchange (PE) with albumin replacement was able to modify Aβ concentrati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boada, Mercè, Anaya, Fernando, Ortiz, Pilar, Olazarán, Javier, Shua-Haim, Joshua R., Obisesan, Thomas O., Hernández, Isabel, Muñoz, Joan, Buendia, Mar, Alegret, Montserrat, Lafuente, Asunción, Tárraga, Lluís, Núñez, Laura, Torres, Mireia, Grifols, Joan Ramon, Ferrer, Isidre, Lopez, Oscar L., Páez, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5240541/ https://www.ncbi.nlm.nih.gov/pubmed/27911295 http://dx.doi.org/10.3233/JAD-160565

Ejemplares similares

Neuropsychological, neuropsychiatric, and quality‐of‐life assessments in Alzheimer's disease patients treated with plasma exchange with albumin replacement from the randomized AMBAR study
por: Boada, Mercè, et al.
Publicado: (2021)

Plasma exchange for Alzheimer's disease Management by Albumin Replacement (AMBAR) trial: Study design and progress
por: Boada, Mercè, et al.
Publicado: (2019)

Longitudinal Neuroimaging Analysis in Mild-Moderate Alzheimer’s Disease Patients Treated with Plasma Exchange with 5% Human Albumin
por: Cuberas-Borrós, Gemma, et al.
Publicado: (2017)

Feasibility, safety, and tolerability of two modalities of plasma exchange with albumin replacement to treat elderly patients with Alzheimer's disease in the AMBAR study
por: Boada, Mercè, et al.
Publicado: (2022)

A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR Study
por: Boada, Mercè, et al.
Publicado: (2020)

Increased Albumin Oxidation in Cerebrospinal Fluid and Plasma from Alzheimer’s Disease Patients
por: Costa, Montserrat, et al.
Publicado: (2018)

Neuroimaging analyses from a randomized, controlled study to evaluate plasma exchange with albumin replacement in mild-to-moderate Alzheimer’s disease: additional results from the AMBAR study
por: Cuberas-Borrós, Gemma, et al.
Publicado: (2022)

Patient Engagement: The Fundació ACE Framework for Improving Recruitment and Retention in Alzheimer’s Disease Research
por: Boada, Mercè, et al.
Publicado: (2018)

Blood Amyloid Beta Levels in Healthy, Mild Cognitive Impairment and Alzheimer’s Disease Individuals: Replication of Diastolic Blood Pressure Correlations and Analysis of Critical Covariates
por: Ruiz, Agustín, et al.
Publicado: (2013)

Correction: Blood Amyloid Beta Levels in Healthy, Mild Cognitive Impairment and Alzheimer’s Disease Individuals: Replication of Diastolic Blood Pressure Correlations and Analysis of Critical Covariates
por: Ruiz, Agustín, et al.
Publicado: (2014)

Association between cell-bound blood amyloid-β(1–40) levels and hippocampus volume
por: Sotolongo-Grau, Oscar, et al.
Publicado: (2014)

Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study
por: Pérez-Grijalba, Virginia, et al.
Publicado: (2019)

Cognitive Composites Domain Scores Related to Neuroimaging Biomarkers within Probable-Amnestic Mild Cognitive Impairment-Storage Subtype
por: Espinosa, Ana, et al.
Publicado: (2017)

Cut-off Scores of a Brief Neuropsychological Battery (NBACE) for Spanish Individual Adults Older than 44 Years Old
por: Alegret, Montserrat, et al.
Publicado: (2013)

Correction: Cut-off Scores of a Brief Neuropsychological Battery (NBACE) for Spanish Individual Adults Older than 44 Years Old
por: Alegret, Montserrat, et al.
Publicado: (2014)

Plasma extracellular vesicles reveal early molecular differences in amyloid positive patients with early-onset mild cognitive impairment
por: Cano, Amanda, et al.
Publicado: (2023)

Identification of undiagnosed dementia cases using a web‐based pre‐screening tool: The MOPEAD project
por: Rodrigo, Adrián, et al.
Publicado: (2021)

Plasma exchange with albumin replacement and disease progression in amyotrophic lateral sclerosis: a pilot study
por: Povedano, Mónica, et al.
Publicado: (2021)

BIOFACE: A Prospective Study of Risk Factors, Cognition, and Biomarkers in a Cohort of Individuals with Early-Onset Mild Cognitive Impairment. Study Rationale and Research Protocols
por: Esteban de Antonio, Ester, et al.
Publicado: (2021)

Personality Factors and Subjective Cognitive Decline: The FACEHBI Cohort
por: Muñoz, Nathalia, et al.
Publicado: (2020)

Prospective multicentre study of the effect of voluntary plasmapheresis on plasma cholesterol levels in donors
por: Rosa-Bray, M, et al.
Publicado: (2013)

Safety, tolerability and immunogenicity of an active anti-Aβ(40) vaccine (ABvac40) in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase I trial
por: Lacosta, Ana-María, et al.
Publicado: (2018)

Clinical performance of an antibody-free assay for plasma Aβ42/Aβ40 to detect early alterations of Alzheimer’s disease in individuals with subjective cognitive decline
por: Pascual-Lucas, María, et al.
Publicado: (2023)

Macular vessel density in the superficial plexus is not associated to cerebrospinal fluid core biomarkers for Alzheimer’s disease in individuals with mild cognitive impairment: The NORFACE cohort
por: Marquié, Marta, et al.
Publicado: (2023)

Efficacy and safety evaluation of Fanhdi(®), a plasma‐derived factor VIII/ von Willebrand factor concentrate, in Von Willebrand's disease patients undergoing surgery or invasive procedures: A prospective clinical study
por: Jimenez‐Yuste, Victor, et al.
Publicado: (2021)

Progression of Blood-Brain Barrier Leakage in Patients with Alzheimer’s Disease as Measured with the Cerebrospinal Fluid/Plasma Albumin Ratio Over Time
por: Musaeus, Christian Sandøe, et al.
Publicado: (2023)

Managing Clinical Trials for Alzheimer’s Disease During the COVID-19 Crisis: Experience at Fundació ACE in Barcelona, Spain
por: Abdelnour, Carla, et al.
Publicado: (2020)

Spectral counting assessment of protein dynamic range in cerebrospinal fluid following depletion with plasma-designed immunoaffinity columns
por: Borg, Jacques, et al.
Publicado: (2011)

Social Representation of Dementia: An Analysis of 5,792 Consecutive Cases Evaluated in a Memory Clinic
por: Cañabate, Pilar, et al.
Publicado: (2017)

Apolipoproteins and their subspecies in human cerebrospinal fluid and plasma
por: Koch, Manja, et al.
Publicado: (2017)

The role of sex and gender in the selection of Alzheimer patients for clinical trial pre-screening
por: Rosende-Roca, Maitee, et al.
Publicado: (2021)

Reliable Measurements of the β-Amyloid Pool in Blood Could Help in the Early Diagnosis of AD
por: Pesini, Pedro, et al.
Publicado: (2012)

Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma
por: De Mattos-Arruda, Leticia, et al.
Publicado: (2015)

The MAPT H1 Haplotype Is a Risk Factor for Alzheimer’s Disease in APOE ε4 Non-carriers
por: Sánchez-Juan, Pascual, et al.
Publicado: (2019)

THE INFLUENCE OF PLASMA PROTEIN ON THE CHLORIDE CONTENT OF THE CEREBROSPINAL FLUID
por: Coombs, Herbert I., et al.
Publicado: (1932)

Vitamin B6 in Plasma and Cerebrospinal Fluid of Children
por: Albersen, Monique, et al.
Publicado: (2015)

The Catabolism of Plasma Albumin in the Rabbit : Its rate and regulation
por: Reeve, E. B., et al.
Publicado: (1959)

Effects of Plasma Albumin on the Pharmacokinetics of Esomeprazole in ICU Patients
por: Tian, Hsin, et al.
Publicado: (2018)

From Face-to-Face to Home-to-Home: Validity of a Teleneuropsychological Battery
por: Alegret, Montserrat, et al.
Publicado: (2021)

Experience of therapeutic plasma exchange in rheumatic diseases: Albumin may be a suitable substitute for plasma
por: Bai, Zhiqian, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vjjip4m8fndad0skjb05t0lhrn